Results 61 to 70 of about 25,773 (228)
Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversion. [PDF]
UNLABELLED:It has been observed that enlargement of perihepatic lymph nodes may be seen in patients with chronic hepatitis B, particularly during acute flares of CHB.
Yen-Ling Ko +9 more
doaj +1 more source
One‐year reassessment of type IV collagen 7S, supported by quantitative M2BPGi‐Qt assessment, helped refine long‐term hepatocellular carcinoma risk stratification in patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy. On‐treatment 4COL7S emerged as a novel marker of residual fibrosis‐related HCC risk.
Kazumi Yamasaki +9 more
wiley +1 more source
Association between HBV genotype, HBeAg status and viral load.
GT, genotype; HBV DNA, hepatitis B viral DNA; HBeAg, hepatitis B e antigenAssociation between HBV genotype, HBeAg status and viral load.
Leland Yee (706287) +7 more
core +1 more source
Abstract Introduction Infection with hepatitis D virus (HDV) is known to accelerate the progression of liver disease and is associated with mortality in individuals with HIV and hepatitis B virus (HBV). However, little is known about current HDV epidemiology, including HDV‐testing practices and prevalence, in this population in Europe.
Anders Boyd +18 more
wiley +1 more source
Major proportion of HBeAg positive subjects were associated with higher HBV DNA levels compared to HBeAg negative subjects.
Debraj Saha (452305) +10 more
core +1 more source
Background & Aims: Antiviral treatment from hepatitis B envelope antigen (HBeAg)-positive status may attenuate the integration of hepatitis B virus DNA into the host genome causing hepatocellular carcinoma (HCC).
Lee HA +34 more
core +2 more sources
Hepatitis B in Organ Transplantation—Current Evidence and Clinical Gaps
ABSTRACT Over the past several decades there have been significant advances in nucleos(t)ide analogue (NA) antiviral therapy for hepatitis B virus (HBV) and global expansion of primary prevention through immunization. Despite this, HBV remains a leading cause of chronic liver disease globally, affecting over 250 million people.
Oscar A. Fernandez‐Garcia +3 more
wiley +1 more source
Objective To investigate the efficiency of pegylated interferon α therapy for patients with HBeAg-positive chronic hepatitis B (CHB) and explore whether liver histopathological features and other factors might influence HBeAg seroconversion.
Cheng-liang Zhu +4 more
core +1 more source
The clinical significance of the coexistence of hepatitis B e antigen (HBeAg) and antibodies against HBeAg (anti-HBe) in patients with chronic hepatitis B (CHB) remains unclear.
Ruifei Xue +14 more
doaj +1 more source

